SBC Medical Group initiated with a Buy at BTIG

BTIG analyst Sam Eiber initiated coverage of SBC Medical Group (SBC) with a Buy rating and $8 price target SBC is the leading aesthetic medical group in Japan with more than 250 franchises and over 6.5M annual patient visits, the analyst tells investors in a research note. The firm says the shares represent an opportunity for investors looking to own an outside of the U.S. business that has “numerous growth prospects” and is trading at a discount to peers.